JAGX — Jaguar Health Share News
0.000.00%
Last trade - 00:00- $4.36m
- $14.44m
- $11.51m
Brief: Jaguar Health Plans To Submit Investigational New Drug (Ind) Application In Q2 2023 To FDA For Crofelemer For Microvillus Inclusion Disease
Jaguar Health Inc expected to post a loss of $9.75 a share - Earnings Preview
Brief: Jaguar Health Regains Compliance With Nasdaq’s Bid Price Requirement
U.S. RESEARCH ROUNDUP-RingCentral, Samsara, Wells Fargo & Co
Brief: Jaguar Health And Filament Health Form Joint Venture Magdalena Biosciences
Brief: Jaguar Health Inc - On Jan 5, 2023, Co Received Notice From Nasdaq Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
Jaguar Health Inc reports results for the quarter ended in September - Earnings Summary
Jaguar Health Inc expected to post a loss of 7 cents a share - Earnings Preview
Brief: Jaguar Health Says Entered Into An Amended And Restated License And Services Agreement With Synworld Technologies Corp
Brief: Jaguar Health Inc - On August 24, Entered Into A Royalty Interest Purchase Agreement
Brief: Streeterville Capital LLC Reports 9.75% Passive Stake In Jaguar Health Inc
Jaguar Health Inc reports results for the quarter ended in June - Earnings Summary
Jaguar Health Inc expected to post a loss of 22 cents a share - Earnings Preview
Brief: Jaguar Health got notice from NASDAQ granting an additional 180 days to regain compliance with minimum bid price requirement
Jaguar Health Inc expected to post a loss of 22 cents a share - Earnings Preview
Brief: Jaguar Health Inc's Unit Napo Pharmaceuticals Entered Into An Amended And Restated License Agreement
Brief: Jaguar Health Enters Exclusive Crofelemer License, Commercialization Agreement With Synworld Technologies For Canalevia
Brief: Filament Health And Jaguar Health Sign Letter Of Intent To Develop Drugs For Specific Mental Health Indications
Jaguar Health Inc reports results for the quarter ended in March - Earnings Summary